Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Sibeprenlimab by Visterra for IgA Nephropathy (Berger's Disease): Likelihood of Approval
Sibeprenlimab is under clinical development by Visterra and currently in Phase III for IgA Nephropathy (Berger's Disease). According to GlobalData,...